Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a biotechnology company focused on developing novel therapeutics. The company is gaining attention due to a recent price target adjustment by Piper Sandler, which set a new target of $37, up from $27.50. This suggests a potential increase of 54.23% from its current price of $23.99, as highlighted by TheFly.
The stock has received a "Moderate Buy" consensus from eight brokerages. Among these, six analysts recommend buying, one suggests a strong buy, and one advises selling. The average one-year target price is $30.20. Notably, Wells Fargo increased its price target from $22.00 to $30.00, giving an "overweight" rating.
GLUE's stock price has shown some volatility, with a recent increase of 1.14% or $0.27, reaching a high of $24.12 and a low of $23.25 today. Over the past year, the stock has fluctuated between $3.50 and $25.77. The company's market capitalization is approximately $1.56 billion, with a trading volume of 1,385,520 shares on the NASDAQ.
Recent analyst activity includes Weiss Ratings reiterating a "sell" rating, while Cowen reaffirmed a "buy" rating. Jefferies Financial Group also maintained a "buy" rating. These varied opinions reflect differing views on the company's future performance, contributing to the stock's current market dynamics.
